Ready to harvest its PD-L1, Alphamab reloads with $60M to nurture the bispecific patch
Alphamab’s $100 million Series A last November for the oncology unit marked its first venture round in almost 10 years of existence. As it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
